These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 3632297)

  • 1. The effects of heparin on the activated partial thromboplastin time of the College of American Pathologists Survey specimens. Responsiveness, precision, and sample effects.
    Gawoski JM; Arkin CF; Bovill T; Brandt J; Rock WA; Triplett DA
    Arch Pathol Lab Med; 1987 Sep; 111(9):785-90. PubMed ID: 3632297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A survey of aPTT reporting in Canadian medical laboratories. The need for increased standardization. Thrombosis Interest Group of Canada.
    Brigden ML; Johnston M
    Am J Clin Pathol; 2000 Aug; 114(2):276-82. PubMed ID: 10941344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laboratory monitoring of heparin. Effect of reagents and instruments on the activated partial thromboplastin time.
    Brandt JT; Triplett DA
    Am J Clin Pathol; 1981 Oct; 76(4 Suppl):530-7. PubMed ID: 7282639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of APTT reagent sensitivity to factor IX and factor IX assay performance. Results from the College of American Pathologists Survey Program.
    Brandt JT; Arkin CF; Bovill EG; Rock WA; Triplett DA
    Arch Pathol Lab Med; 1990 Feb; 114(2):135-41. PubMed ID: 2405809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring heparin therapy by the activated partial thromboplastin time--the effect of pre-analytical conditions.
    van den Besselaar AM; Meeuwisse-Braun J; Jansen-Grüter R; Bertina RM
    Thromb Haemost; 1987 Apr; 57(2):226-31. PubMed ID: 3603414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations for appropriate activated partial thromboplastin time reagent selection and utilization.
    Fritsma GA; Dembitzer FR; Randhawa A; Marques MB; Van Cott EM; Adcock-Funk D; Peerschke EI
    Am J Clin Pathol; 2012 Jun; 137(6):904-8. PubMed ID: 22586049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standardization of coagulation tests.
    Opartkiattikul N
    Southeast Asian J Trop Med Public Health; 1999; 30 Suppl 3():79-85. PubMed ID: 10926265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of aprotinin on the response of the activated partial thromboplastin time (APTT) to heparin.
    Francis JL; Howard C
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):35-40. PubMed ID: 7681330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discard volumes necessary for clinically useful coagulation studies from heparinized Hickman catheters.
    Mayo DJ; Dimond EP; Kramer W; Horne MK
    Oncol Nurs Forum; 1996 May; 23(4):671-5. PubMed ID: 8735325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays.
    Kitchen S; Preston FE
    Thromb Haemost; 1996 May; 75(5):734-9. PubMed ID: 8725715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of inaccurate blood sample volume on prothrombin time (PT) and activated partial thromboplastin time (aPTT).
    Peterson P; Gottfried EL
    Thromb Haemost; 1982 Apr; 47(2):101-3. PubMed ID: 7101228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A low volume specimen container suitable for monitoring the aPTT of heparinized patients.
    Ray MJ; Carroll PA; Just SJ; Hawson GA
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):805-7. PubMed ID: 8292732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
    Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
    Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of coagulation values obtained from a heparinized central venous catheter.
    Pinto KM
    Oncol Nurs Forum; 1994 Apr; 21(3):573-5. PubMed ID: 8052553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The APTT monitoring of heparin--the ISTH/ICSH collaborative study.
    Van der Velde EA; Poller L
    Thromb Haemost; 1995 Jan; 73(1):73-81. PubMed ID: 7740500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of lupus anticoagulants on the activated partial thromboplastin time. Results of the College of American Pathologists survey program.
    Brandt JT; Triplett DA; Rock WA; Bovill EG; Arkin CF
    Arch Pathol Lab Med; 1991 Feb; 115(2):109-14. PubMed ID: 1899555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective.
    Favaloro EJ; Bonar R; Aboud M; Low J; Sioufi J; Wheeler M; Lloyd J; Street A; Marsden K;
    Lab Hematol; 2005; 11(3):157-62. PubMed ID: 16174600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accuracy of drawing coagulation samples from heparinized arterial lines.
    Templin K; Shively M; Riley J
    Am J Crit Care; 1993 Jan; 2(1):88-95. PubMed ID: 8353585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of the activated partial thromboplastin time for heparin monitoring.
    Smythe MA; Koerber JM; Westley SJ; Nowak SN; Begle RL; Balasubramaniam M; Mattson JC
    Am J Clin Pathol; 2001 Jan; 115(1):148-55. PubMed ID: 11190801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of low dose nitroglycerin on plasma heparin concentrations and activated partial thromboplastin times.
    Brack MJ; More RS; Hubner PJ; Gershlick AH
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):183-6. PubMed ID: 8457649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.